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Abstract 
The CDK8 protein found within humans is a unique cyclin-dependent kinase as it is often 
found in a four-protein complex with MED12 and MED13, lacks a phosphorylatable threonine in 
its activation loop and has an extended C-terminus. The goal of this project is to determine 
whether the CDK8 C-terminus is acting as an alternate activation loop to regulate the kinase 
function of CDK8. To test this hypothesis, a unique type of cross-linking was performed on the 
CDK8 module (CDK8, CCNC, MED12, MED13) and truncation mutants of CDK8 were created 
to test the activity of the kinase. The results suggest that instead of the CDK8 C-terminus acting 
as a traditional activation loop, it is instead playing a more structural role by binding to MED12 
and/or MED13. The cross-linking experiment also suggests a more structural role for the CDK8 
C-terminus from identified intramolecular cross-links from the C-terminal domain of CDK8 to 
the rest of CDK8. Since MED12 is required for CDK8 kinase activity, the CDK8 C-terminus 
may be activating the kinase by interacting with and possibly binding MED12. This is an 
interesting finding, as it was largely believed that the CDK8 C-terminus was playing a regulatory 
role rather than a structural role in activating the kinase. Future experiments are proposed to 
further test this finding and find a more specific mechanism for the binding of MED12 to the C-
terminus of CDK8.  
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Chapter I. Introduction 
 
The Mediator Complex 
Within the human body, the process of transcription is a regulated process that involves a 
variety of different proteins and enzymes (Figure 1). One of the most important enzymes 
responsible for controlling transcription is RNA polymerase II, commonly referred to as pol II. 
Pol II requires further regulation from a variety of proteins, which assemble into a pre-initiation 
complex (PIC). Within this large complex, there is a smaller component known as Mediator, 
which is generally required for activated transcription (where DNA is copied into RNA by pol 
II), and whose subunit composition has been shown to vary (Poss, Ebmeier & Taatjes, 2013). 
The Mediator complex has been shown to stabilize or facilitate the formation of the PIC and the 
knockout of various Mediator subunits has been shown as embryonic lethal (Poss, Ebmeier & 
Taatjes, 2013). Additional studies of Mediator in humans suggest that it may also have post-
recruitment activation of pol II, and thus does more than merely recruit pol II to the site of 
transcription activation (Taatjes, 2010).  
 
Figure 1. Mediator helps to activate transcription. A model of the general transcription 
process, showing the important proteins and enzymes involved from the Mediator, RNA 
polymerase II (RNAP II), general transcription factors (GTFs), TFIID, and TFIIH.  
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The human Mediator complex consists of twenty-six subunits and is 1.2 MDa in size, 
which makes it a very large complex (Table 1) (Taatjes, 2010). The general structure consists of 
a head module, a body portion, and a leg and it seems that pol II assembles around the head 
module when assembled with the Mediator complex (Figure 2)  (Taatjes, 2010). In humans, 
Mediator can be inactivated, whereby it can no longer bind with pol II, when Mediator assembles 
with the CDK8 module. The CDK8 module can inhibit Mediator from binding to pol II by 
causing a structural shift, adding a “foot” module onto Mediator (Figure 3). This, in turn, may 
repress transcription in cells by blocking the assembly of the pol II complex into the PIC 
(Taatjes, 2010) and therefore, there is unique interest in the role of the CDK8 module in relation 
to human Mediator.  
Mediator subunit Molecular weight (kDa) Mediator subunit Molecular weight (kDa) 
MED1 220 MED21 19 
MED4 36 MED22 16 
MED6 33 MED23 130 
MED7 34 MED24 100 
MED8 32 MED25 92 
MED9 16 MED26 70 
MED10 16 MED27 37 
MED11 13 MED28 20 
MED14 150 MED29 24 
MED15 105 MED30 25 
MED16 95 MED31 18 
MED17 78 CDK8 55 
MED18 28 CCNC 34 
MED19 26 MED12 240 
MED20 23 MED13 250 
Table 1. Mediator subunits and their corresponding molecular weights. The CDK8 module 
subunits are shown in red. (Poss, Ebmeier & Taatjes, 2013). 
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Figure 2. Mediator-pol II causes structural changes in Mediator. A schematic outlining how 
Mediator structurally changes after pol II binding. Pol II is shown in red and can be seen binding 
the head region of the Mediator complex. (Taatjes, Ebmeier & Taatjes, 2013) 
 
 
Figure 3.  CDK8-Mediator Inhibits pol II Binding. CDK8 module-Mediator 
binding appears to occlude pol II-Mediator binding by an allosteric mechanism. EM 
structures of Mediator and CDK8-Mediator are shown (Taatjes et al, 2002). The lower 
panel shows “bottom” views of each complex. The bracket shows the general region 
occupied by pol II upon binding human Mediator, and the corresponding position in 
the CDK8-Mediator complex. (Poss, Ebmeier & Taatjes, 2013).  
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The CDK8 Module and Human Mediator 
A distinct form of Mediator, which is of primary interest to this project, is the CDK8-
Mediator complex. The CDK8 module is made up of four different subunits: CDK8, cyclin C 
(CCNC), MED12, and MED13. The CDK8 module reversibly associates with human Mediator 
and its function appears to switch off transcription by phosphorylating cyclin H, a subunit within 
TFIIH (Akoulitchevl et al., 2000), which is a general transcription factor in the PIC. Knockout of 
CDK8 has been shown to be embryonic lethal in mice, while CDK8 has been identified as a 
colon cancer oncogene and its kinase activity is required for oncogenesis (Firestein et al., 2008; 
Morris et al. 2008). Based on these studies, it can be seen that the kinase activity of CDK8 plays 
an important biological role in humans, but it remains less clear how the kinase activity is more 
specifically regulated.  
The CDK8 module has also been shown to block Mediator binding to the pol II C-
terminal domain (CTD) by binding to Mediator and causing a structural shift that alters the pol II 
CTD binding site (Figure 3) (Poss, Ebmeier & Taatjes, 2013). When Mediator can no longer 
bind to pol II, transcription initiation is repressed, whereby pol II stops copying DNA into RNA. 
Additionally, CDK8 has been shown to phosphorylate the CTD of pol II, separately from 
Mediator (Knuesel et al., 2009; Ebmeier & Taatjes, 2010; Näär et al., 2002; Elmlund et al., 
2006). CDK8 can phosphorylate the pol II C-terminal domain, which then disrupts Mediator 
binding due to the CTD becoming hyperphosphorylated and transcription becomes repressed in-
vitro (Knuesel et al., 2009; Ebmeier & Taatjes, 2010; Näär et al., 2002; Elmlund et al., 2006). 
Overall, the CDK8 module as a whole has been linked to a variety of biologically important 
functions, but there are several ways in which CDK8 is unique among kinases.  
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An interesting point is that CDK8 can exist separately, apart from MED12 and MED13, 
with only CCNC (Knuesel et al., 2009). Looking at the dimer form, CDK8-CCNC is modestly 
conserved, at the primary amino acid level, in yeast in comparison to humans. In yeast, the 
CDK8-CCNC dimer is instead known as Srb10-Srb11. Both yeast and human CDK8 modules 
have shown to reversibly bind Mediator, both have been shown to be able to repress and activate 
DNA-binding transcription factors by phosphorylation, and both bind Mediator through their 
respective MED13 subunits (Knuesel et al., 2009; Tsai et al., 2013). The kinase activity of both 
yeast and human CDK8 modules is also very similar, as yeast CDK8 has been shown to 
phosphorylate different activators to alter their activity or stability and can phosphorylate the 
CTD of RNA pol II to repress transcription (Hengartner et al., 1998). Finally, there is some 
sequence homology between human and yeast CDK8 module subunits (Poss, Ebmeier & Taatjes, 
2013), again suggesting a biological importance to the CDK8 module since it can be found, in 
varied forms, across evolutionarily divergent organisms  
Out of the four proteins that make up the CDK8 module, of primary interest are CDK8 
and MED12. MED12 and CDK8 have both been proven to interact with a variety of DNA-
binding transcription factors (Poss, Ebmeier & Taatjes, 2013), suggesting the ability of the 
CDK8 module to act independently of Mediator. Notably, MED12 was shown to be required for 
CDK8 activity in human cells, as the three-protein complex containing CDK8, CCNC, and 
MED12 was active when testing kinase function, while the three-protein complex instead 
containing MED13 was not active (Figure 4) (Knuesel et al., 2008). As well, MED12 has been 
implicated in prostate cancer, as well as drug resistance in certain cancer types (Huang et al., 
2012; Barbieri et al, 2012), making it an important subunit to study in relation to the CDK8 
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module. Yet, what is not known at this time is how the CDK8-CCNC dimer interacts with 
MED12 and MED13, which may be related to a unique part of CDK8, its extended C-terminus. 
 
Figure 4. MED12 is required for kinase activity. Kinase assays of the complexes, either wild-
type (wt) or kinase dead (kd), meaning the kinase activity is inactive. The second figure 
additionally shows how the kinase activity of CDK8 can phosphorylate the CTD, again with the 
different complexes (Knuesel et al., 2008). 
 
In nature, there are a variety of cyclin dependent kinases (CDKs) that often share many 
structural features, such as an N-terminal lobe that binds different cyclins (Schneider et al., 
2011). As well, many CDKs are auto-phosphorylated at a conserved threonine (T) residue in 
their activation loops, often referred to as a T-loop (Johnson et al., 1996). A typical mechanism is 
that once the T residue is phosphorylated in the activation loop, a structural shift is initiated that 
causes the loop to become less ordered and move away from the substrate binding pocket, 
allowing the substrate to bind (Figure 5) (Johnson et al., 1996).What is unique about CDK8 is its 
lack of this T residue and in the place of threonine, CDK8 contains and aspartate (D) in its 
activation loop (Figure 6). Another unique feature of CDK8 is that it has an extended C-
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terminus, not found in lower eukaryotes, the purpose of which is unknown but may play an 
important role in the activation of CDK8 (Figure 7). This activation role is supported by previous 
data that suggests residue T411, in the CDK8 CTD, may be phosphorylated in the active kinase 
and thus acting as an alternate activation loop (Knuesel, 2009).  
 
Figure 5. Activation loop of a general protein kinase. The activation loop contains the primary 
phosphorylation site (T197). The P+1 loop forms a pocket that forms a pocket to accommodate 
other phosphorylated residues (Taylor and Kornev, 2010).  
 
 
Figure 6. Alignments of the activation loop regions in various CDKs. The activation loop 
T, t160 within CDK2 (green), is conserved among all CDKs except CDK8 and its paralogs. 
CDK2 T160 aligns with D304 in yeast CDK8 and D173 in human CDK8 and CDK8L (red). 
Hs: Homo sapiens. (Knuesel, 2009).  
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Figure 7. Sequence alignment of CDK2 and CDK8 with CDK domains color-coded. Identical 
residues are shaded dark grey and similar residues are shaded light grey. Note the extended C-
terminal domain of CDK8, 117 residues longer than the CTD of CDK2. Alignments were done 
using ClustalW (Knuesel, 2009).  
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Hypothesis and Goals  
For this project, there are two different goals, both related to determining the function of 
the extended C-terminus of CDK8, since it is rather unique among CDKs and it’s structure has 
not been able to be determined with crystallography. The first goal is to determine the 
architecture and molecular interfaces within the CDK8 module as the current data lack the 
structure of the entire module. The second is to determine the regulatory role, if any, for the CTD 
of CDK8.  
 The first part of the project was to analyze the CDK8 module with a cross-linking/mass 
spectrometry (CXMS) method that would be able to identify any links between CDK8 and 
CCNC and MED12. The CXMS methodology is discussed more thoroughly in Chapter II. If 
cross-links were identified, it would point to the possibility that the C-terminus is important for 
binding CCNC and/or MED12. This information could show insights into the molecular 
architecture of the CDK8 module, as well as any possible interfaces within the module with the 
CTD of CDK8. The second part of the project was to look at the C-terminus in terms of its 
possible function in regulating kinase activity. Since CDK8 lacks the usual T-loop, due to 
presence instead of an aspartate (D) residue, which cannot be phosphorylated (Figure 6) it may 
have an alternate activation loop and be phosphorylated at a different residue, like T411.  
For this project, to address the possible mechanisms that the C-terminus may be involved 
in for activation of the kinase, there were multiple hypotheses. The first hypothesis was that 
CDK8 contains an alternate activation loop that is found in its extended C-terminus. The second 
hypothesis was that MED12 interactions with CDK8:CCNC facilitate the activation of the 
kinase. My predictions for this project were then that the cross-linking with MED12 and 
CDK8:CCNC would identify critical residues for kinase activation of CDK8. As well, if there is 
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any site that needs to be phosphorylated for the kinase to be active, by truncating the C-terminus, 
CDK8 will become active since the active site will no longer be blocked. The following 
experiments and data address these hypotheses and goals.  
     
            Figure 8. The overall structure and goals of the project for easy reference. 
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  of	  CDK8	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Chapter II. Molecular Architecture of CDK8 Module 
 
A. Introduction 
Cross-linking/Mass Spectrometry Methodology (CXMS) 
For one part of my thesis project, I worked in close collaboration with the Institute for 
Systems Biology and the lab of Dr. Jeff Ranish to figure out interactions within the CDK8-
CCNC two-protein module and the CDK8-CCNC-MED12 three-protein module. The crystal 
structure of the CDK8-CCNC dimer is fairly well known (Schneider et al., 2011), so when 
looking at the dimer, the initial goal was to prove that using this CXMS method was viable for 
this protein complex as the CXMS data could be compared to the known crystal structure. The 
Ranish lab uses different cross-linkers, and for this particular project the cross-linker is 
Bis(sulfosuccinimidyl) suberate (BS3) (Figure 9). BS3 works by forcing lysine groups, which are 
amino acids with nitrogen in them, to form a bond, or cross-link, if the residues are 
approximately within 11.4 Å. Then mass spectrometry (MS) is used to separate the two cross-
linked residues by their mass and charge, which allows the two residues to individually be 
identified by how they broke apart in MS (Luo et al., 2012). Then each identified residue can be 
matched to its location on the protein in question from its primary sequence. This information 
can then tell the lab how many protein interactions there are between two different proteins, like 
CDK8 and CCNC, and therefore give us structural interfaces within the protein dimer. The same 
method can then be applied to larger modules, particularly the three-protein module with 
MED12.  
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Figure 9. The structure of the cross-linker group, BS3. The Ranish Group uses this for CXMS 
(Thermo Fisher Scientific, 2014) 
 
As mentioned above, the goal is to pay close attention to the extended C-terminus of 
CDK8 to determine if this part of the protein is linked in any way to either CCNC or MED12, 
which would give a structural purpose to this C-terminus. As well, it may provide insights into 
the molecular architecture and organization of the entire CDK8 module, which is largely 
unknown. 
 
B. Results 
Purification of CDK8-CCNC Dimers and CDK8-CCNC-MED12 Modules 
 The first step of the cross-linking process is to purify the CDK8:CCNC complex in order 
to provide pure samples to the Ranish Lab. Initially, the methods used to purify the dimer with 
CDK8 and CCNC was attempted with E.coli, but this was stopped as the dimer was shown to be 
inactive in a kinase assay. The next attempt was to instead purify the dimer from insect cells. The 
pellets were spun down in lysis buffer, then the supernatant was removed after spinning down 
the cells, and the dimer was purified from the whole cell extract (WCE) using glu-glu peptide. In 
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order to estimate the concentration of the dimer that would be purified from the insect cells, 
previous purifications of the CDK8-CCNC dimer (with the point mutation T411E) were 
quantified using a SYPRO Ruby gel stain (Figure 10). Then, purifications were compared using 
a silver stain to estimate how close the concentrations were to the T411E mutant (Figure 11) and 
a western was run to ensure that both CDK8 and CCNC were present and no MED12 or MED13 
proteins were present (Figure 12).   
 
75 
 
50 
 
37 
 
 
25 
 
20 
 
15 
 
 
 
MW(kDa)    5µL       2µL      0.5µL 
Figure 10. A SYPRO gel of CDK8-
CCNC T411E mutant. Used to quantify 
the approx. concentration of the dimer 
from insect cell purifications. 5µL, 2µL, 
and 0.5µL of the purification were added. 
The top bands (around 55kDa) are CDK8 
bands and the bottom bands (around 
33kDa) are CCNC. The determined 
CCNC concentration was 0.602 µM. 
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Once the purification was shown to be successful, the elutions were concentrated and sent 
to the lab of Dr. Jeff Ranish at the Systems Biology Institute in Seattle, WA. A very similar 
protocol was followed for the 3-protein module, containing CDK8, CCNC, and MED12. Again, 
the purifications were tested with a western (Figure 13) to ensure the presence of each of the 3-
protein module components and no MED13.  
In order to ensure a 1:1:1 molar ratio for each module component, a glycerol gradient was 
used to try and separate out any free CDK8-CCNC dimer that was not linked with MED12 
(Figure 14). Multiple gradients were used to amass the largest amount of CDK8-CCNC-MED12 
module and the estimated concentration, from a SYPRO Ruby, for MED12 was 0.05µM. The 
samples were then combined, concentrated, and a buffer exchange was performed and the 
sample was shipped to the Ranish lab for analysis. 
 
Figure 11 (left). A silver stain of the CKD8:CCNC purified elutions. Lane 2 is 1µL of 
CDK8:CCNC, Lane 3 is 2µL of CDK8:CCNC. The purification was estimated to produce a 
concentration of CCNC at 0.602µM. Figure 12 (right). A western of the CDK8:CCNC 
elutions. Used to ensure the presence of CDK8 and CCNC only. Lane 1 is 1µL of 
CDK8:CCNC, lane 2 is 2µL of CDK8:CCNC. 
CDK8 
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Figure 14. A silver stain of MED12, CDK8, and CCNC. This gel shows 
the odd fractions of a 15-30% gradient. The components become 
concentrated in the very last fraction (25). From a SYPRO Ruby gel, the 
concentration of MED12 was estimated to be 0.05µM in the final fraction.  
  Input    1     3      5      7      9    11   13    15   17   19    21    23     25    
MED12 
CDK8 
CCNC 
250 
150  
100  
75 
 
50 
 
37 
 
25 
 
Figure 13. A Western of the 3wt purification. Shows the presence of MED12, 
CDK8, and CCNC but no MED13.  
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Cross-linking Data for the CDK8-CCNC Dimer and CDK8-CCNC-MED12 Module 
 The samples for both the CDK8-CCNC dimers and CDK8-CCNC-MED12 modules were 
run through the mass spectrometry procedure used by the Ranish lab. The results are laid out 
with each line connecting two residues that were shown to be cross-linked. For the CDK8-CCNC 
module (Figure 15), the sequence of CCNC is laid out on the top and the CDK8 sequence is on 
the bottom. For the CDK8-CCNC-MED12 module, the very top figure represents CCNC, CDK8 
is laid out in the middle, and MED12 is the very bottom figure (Figure 16).  
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 Figure 15. CXMS Data from CDK8-CCNC dimers. This demonstrates what the cross-linking data received from 
the Ranish lab with residues from cyclin C (CCNC – top) interact with residues from CDK8 (bottom). The lines 
connecting the top to the bottom show the cross-links. Red dots indicated cross-linked residues, blue indicates 
residues that were not cross-linked, but could have been. The blue lines that are connected by red dots represent 
intramolecular cross-links between two residues on the same protein.  
 22 
Figure 16. CXMS Data for CDK8-CCNC-MED12. The very top figure is CCNC’s primary sequence, the middle is CDK8’s sequence, 
and the very bottom, and longest, sequence is MED12. Again, the blue dots represent residues that could be cross-linked while red dots 
represent residues that have been cross-linked. The lines between the proteins represent which residues were cross-linked, and the lines 
above the sequences represent all intramolecular cross-links.  
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C. Discussion 
Cross-linking with CDK8:CCNC 
 One of the main purposes of cross-linking the CDK8:CCNC dimer was to verify that the 
CXMS method could be used to cross-link the CDK8 module. Based on the results, the method 
does work as the cross-linking data identifies some interactions that were previously identified 
from the crystal structure of CDK8:CCNC (Table 2, Figure 17).  
CDK8 Residue CCNC Residue CDK8 Residue CCNC Residue 
153 79 47 117 
8 79 322 117 
119 248 26 126 
153 248 170 126 
44 248 153 126 
74 248 242 126 
26 248 37 126 
242 248 44 126 
170 248 281 248 
265 248 355 248 
74 248 355 117 
26 117 8 117 
242 117 355 126 
153 117 
 
Table 2. CXMS Identified Residues for CDK8-CCNC Dimer. This table shows all of the 27 
identified cross-links from the CXMS data. The pink highlighted residues are those with high-
confidence (81%) and the yellow highlighted residues are low-confidence. 
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CDK8 Residue CCNC Residue Distance (Å) 
8 79 26.8 
44 248 62.4 
74 248 52.6 
26 117 49.4 
153 117 50.7 
170 126 54.8 
 
Figure 17. CXMS Intermolecular Data with the crystal structure of CDK8-CCNC. CDK8 is 
green with CCNC blue and the cross-linked lysine (K) residues labeled along with the length (in 
Å) of the cross-link. The table lists the cross-linked residues, along with the distances between 
the residues.  
 
The cross-links depicted in Figure 17 do not represent all of the identified cross-links but 
show the capability of using the CXMS methodology to identify intermolecular cross-links in the 
CDK8-CCNC dimer. This then shows that the same methodology could be used to identify 
cross-links between CDK8, CCNC, and MED12. It is important to note, however, that the spacer 
length for the cross-linker used, BS3, is only 11.4 Å, while the cross-links identified are all 
longer than the spacer length. There could be multiple possibilities for these results, such as 
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multiple BS3 cross-linkers being linked between two lysines, increasing the length of the cross-
link. As well, it could be that the structure of the dimer is more mobile than the crystal structure 
suggests, creating longer lengths between residues (Rappsilber, 2010). Still, overall, there was 
great success in cross-linking between the heterodimer that proved the efficacy of the CXMS 
methodology.  
As well, the cross-linking data showed that there quite a few intramolecular cross-links 
between the two proteins (Table 3, Table 4, Figure 18), suggesting that there may be a lot of 
contacts within CDK8 that may play an important role in the structure and function of the kinase. 
Looking closer at the C-terminus of CDK8, however, shows no cross-links at any of the possible 
residues: 370, 371, 402, or 403. This is not surprising as it is well known that cyclin C binds at 
the N-terminal lobe rather than the C-terminus (Schneider et at., 2011). Nevertheless, by proving 
the efficacy of the CXMS method, this allowed for the next step of purifying the three-protein 
complex, with CDK8, CCNC and MED12.  
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CDK8 Residue CDK8 Residue CDK8 Residue CDK8 Residue 
119 26 26 322 
52 52 115 119 
153 153 170 37 
153 52 170 8 
153 8 170 355 
153 37 170 74 
153 44 170 26 
153 26 170 170 
153 295 170 242 
153 242 170 47 
153 170 170 322 
153 265 242 26 
37 41 242 265 
37 8 47 74 
37 44 322 322 
44 74 271 271 
355 39 119 119 
355 37 119 355 
355 44 52 8 
74 8 153 355 
26 39 153 322 
26 52 355 355 
26 281 355 370 
26 8 35 47 
26 37 26 44 
26 367 115 355 
26 355 47 52 
26 74 322 355 
 
Table 3. CXMS Identified Intramolecular cross-links in CDK8. The high-confidence cross-
links are highlighted in pink (90%) and low-confidence cross-links are highlighted in yellow.  
 
CCNC Residue CCNC Residue 
248 248 
117 248 
117 126 
126 248 
126 261 
248 117 
 
Table 4. CXMS Identified Intramolecular cross-links in CCNC. The high-confidence cross-
links are highlighted in pink (70%) and low-confidence cross-links are highlighted in yellow. 
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CDK8 Residue #1 CDK8 Residue #2 Distance (Å) 
153 170 20.9 
37 41 17.5 
37 44 22.9 
CCNC Residue #1 CCNC Residue #2 Distance (Å) 
117 126 16.4 
126 248 24.7 
126 261 22.2 
Figure 18. CXMS Intramolecular Data with the crystal structure of CDK8-CCNC. 
Intramolecular cross-links identified from the CXMS methodology plotted onto the crystal 
structure of CDK8-CCNC. CDK8 is green and CCNC is green and the cross-linked lysines are 
labeled. The table lists the cross-linked residues and the distances between residues.  
 
 
Cross-linking with MED12 
 
 The reason for cross-linking data the 3-protein complex, CDK8:CCNC:MED12, is to 
determine the architecture of the module to identify any interfaces, with close attention paid to 
any possible contacts between the C-terminus of CDK8 and MED12. Since MED12 is required 
for the kinase activity of CDK8 (Knuesel et al., 2009), it would be interesting to see any 
interactions between MED12 and CDK8 that would elucidate how MED12 is activating the 
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kinase. From the data, the initial indication seems to be that there are no cross-links present 
between the C-terminus of CDK8 and MED12. Yet, the links that the Ranish group was able to 
identify were all links deemed not “confident”. This suggests that MED12 was underrepresented 
in the samples and so it was hard to identify cross-links with the protein. This may stem from the 
fact that it is hard to get a solid stoichometric ratio between MED12 and CDK8:CCNC due to 
MED12’s large size, which is hard to express in insect cells. Sample may also have been lost in 
the process of concentrating the sample and performing a buffer exchange.  
 Even though there were no MED12-CDK8 C-terminus cross-links that were found from 
this initial cross-linking data, there are a couple possibilities to explain these results, beyond lack 
of enough sample. One possibility is that the CDK8 C-terminus is binding MED13 instead. Then 
MED13 could then be binding to MED12, connecting the module together. If this were 
occurring, there would be no cross-links between the C-terminus of CDK8 and MED12. Another 
possibility is that the CDK8 C-terminus is not binding MED12 and so this CXMS methodology 
cannot be used to determine any important residues in the CDK8 C-terminus that may be helping 
to activate the kinase via interaction with MED12. Ultimately, this initial data suggests that there 
are no cross-links in the C-terminus of CDK8 and MED12, but more sample needs to be sent to 
verify these results. This will be done without a concentration step, as it has just recently been 
found to be unnecessary to achieve “high-confidence” cross-links.  
 Yet there were some cross-linked residues that can be discussed. The cross-links that 
were identified with a low amount of certainty were between CDK8 residues 41 and 44 with 
MED12 residues 1622 and 1526 respectively. This corresponds to the “front” end of the CDK8 
module in the N-terminus, suggesting this could be where MED12 is interacting with CDK8. As 
well, intramolecular links were also identified within the MED12 module, indicating some 
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presence of cross-links between relatively close residues, for example between MED12 residue 
1453 and residue 1463. Since these residues are not very far apart, they could be indicative of an 
intramolecular connection or merely two closely positioned residues. Still, the identified cross-
links do suggest that this method can be used, with more MED12, to identify further cross-links 
between the three proteins.  
 
Future Directions 
 Beyond the immediate direction of purifying more CDK8:CCNC:MED12 complexes to 
send for more cross-linking data, there are more experiments that can be done to look at 
interactions between CDK8’s C-terminus and other proteins in the module. One will be to purify 
and concentrate the whole CDK8 module with MED13 to identify and cross-links between all 
four proteins, with close attention still paid to the C-terminus of CDK8. The CDK8 C-terminus is 
of particular interest, as its purpose is not defined and it may be involved in interactions with 
MED12 or MED13, which would be indicated by cross-links. This experiment could also 
highlight possible residues that are interacting between MED12 and MED13 and MED13 and 
CDK8, beyond the CDK8 C-terminus. Since the structure of the full module is not well known, 
these data could give details about how each protein is interacting with the other proteins in the 
full module, which would be new and useful information. 
Other data, from similar CXMS data with the CDK8-Mediator complex, done by Ben 
Allen in the Taatjes lab, indicates high-confidence cross-links, on CDK8 residues 44 and 74, 
with MED13. Interactions were also found between MED12 and MED13, so one possibility is 
that CDK8 is interacting with MED13 and not MED12, so the three-protein module with 
MED13 could also be purified and sent to CXMS to get a closer look at those interactions. Close 
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attention still needs to be paid to the notion that the CDK8 C-terminus could be interacting with 
the rest of the CDK8 module, somehow causing a conformational change that could then allow 
for CDK8 interactions with MED12 and MED13. This complicated mechanism remains another 
option for the function of the CDK8 C-terminus and further CXMS experiments and data will be 
helpful in figuring the architecture out for the CDK8 module.  
The experiments mentioned above are possible future directions for continuing to use this 
CXMS method to gain insights into the CDK8 module intra- and inter-molecular interactions and 
how these interactions could be affect the kinase activity of CDK8. 
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Chapter III. Role of CDK8-CTD in Regulation of Kinase Activity  
 
A. Introduction 
Kinase Activity of CDK8  
CDK8, along with CCNC, MED12, and MED13, affects transcription by interacting with 
Mediator, which negatively affects Mediator interaction with pol II (Knuesel et al., 2009; 
Ebmeier & Taatjes, 2010; Näär et al., 2002; Elmlund et al., 2006). CDK8 has been shown to also 
phosphorylate cyclin H, which inhibits TFIIH and represses transcription (Akoulitchev et al., 
2000). The kinase activity of CDK8 is required for oncogenesis in colon cancer, based on mouse 
models (Firestein et al., 2008). These examples indicate that the kinase activity of CDK8 plays 
an important role in transcription regulation, which is then dependent on the other subunits, 
mainly MED12 and MED13. MED13 was shown to be critical for allowing the CDK8 module to 
interact with Mediator, allowing the module to repress transcription (Knuesel et al., 2009). More 
importantly for this project, it was found that MED12 is required for the kinase activity of CDK8 
by showing that the CDK8:CCNC:MED12 module was almost as active as the wild-type 
CDK8:CCNC:MED12:MED13 module (Figure 19) (Knuesel et al., 2008). Ultimately, while it is 
known that MED12, and to a lesser extent, MED13, play an important role in the kinase activity 
of CDK8, the mechanisms of their roles within the CDK8 module are not well known.  
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Figure 19. MED12 is required for kinase activity. Kinase assays of the complexes, either 
wild-type (wt) or kinase dead (kd), meaning the kinase activity is inactive. The second figure 
additionally shows how the kinase activity of CDK8 can phosphorylate the CTD, again with the 
different complexes (Knuesel et al., 2008). 
 
B. Results 
Cloning of CDK8 CTD Truncation Mutants  
 Initially, the goal was to clone the truncation mutants with Polymerase Chain Reaction 
(PCR) and digesting the preferred CDK8 sequences and insert the new CDK8 sequence into the 
pACO vector. The restriction endonucleases chosen were XbaI and EcoRI-HF due to their 
presence on the CDK8 sequence in the pACO vector. Yet, this method of cloning did not prove 
to be successful and instead the method used was site directed mutagenesis and a stop codon was 
put into the CDK8 sequence to terminate the protein after residue 357 and residue 403. These 
two truncations were chosen as residue 357 is roughly where similarities end with other CDK 
alignments for the C-terminus in yeast Cdk8 (Srb10) (Figure 20) and residue 403 is the end of 
density from the known crystal structure of the human CDK8-CCNC dimer (Schneider et al., 
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2011). As well, the CDK8 protein up until residue 403 is known to be stable and bind CCNC, 
giving more support as to choosing this residue to truncate the C-terminus.  
 
Figure 20. CDK8 alignment (human) with Srb10 (yeast). Red-highlighted residues are exact 
matches between sequences, while red-lettered residues are similar residues between each 
sequence.  
 
 The sequence was cloned in the pGEX vector, which is optimized for E.coli, and then 
inserted into the pACO vector, which is used for insect cell expression. This method proved to be 
successful, as determined by restriction digestions with additional restriction sites that were also 
cloned in. In CDK8(1-357), the stop codon inserted was TAA and an SspI site (AATATT) was 
added into the sequence. In CDK8(1-403), the stop codon was also TAA and a PmlI site 
(CACGTC) was added into the sequence. An analytical digestion (Figure 21) shows that both 
mutations were successfully inserted into the pGEX vector and the DNA was PCRed out, ligated 
into the pACO vector, and purified using a Maxi-prep and finally sent to UC Denver for insect 
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cell baclovirus infection. The cloned sequences were also then verified with sequencing data to 
ensure the stop codon was inserted after each appropriate residue.  
 
Expression of Mutant CDK8 Modules 
 Each CDK8 truncation mutant (1-357 and 1-403) was sent to UC-Denver for insect cell 
expression in a 2-protein form with CDK8:CCNC and its 4-protein form with 
CDK8:CCNC:MED12:MED13 and all of the modules were purified using the glu-glu antibody 
purification protocol. SYPRO Ruby gels (Figure 22) were used to confirm successful 
purification and to determine the concentrations of each of the modules. For CDK8(1-357) in a 
complex with CCNC, its concentration was 1.04µM based on CDK8 and in its 4-protein form 
(CDK8-CCNC-MED12-MED13), its concentration was 0.11µM based on CDK8. For CDK8(1-
403), its concentration in complex with CCNC was 2.57µM based on CDK8 and in its 4-protein 
(CDK8-CCNC-MED12-MED13) form its concentration was 0.26µM based on CDK8.  
Figure 21. An analytical digestion of truncation mutants, 1-357 and 1-403. The 
first three lanes for each mutant represent different  DNA sequences isolated from 
different E.coli colonies that were chosen. The difference between the control and 
digested lanes show that the truncations were successful.  
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 Further verification was used to ensure that all CDK8 modules were present in their 4-
protein form (Figure 21). For the CDK8(1-403) truncation mutant, all four subunits were present 
based on CCNC, MED12, and MED13 western blot signals. In the CDK8(1-357) truncation 
mutant MED12 and MED13 were not found, but CCNC and CDK8 were still present (Figure 
23). CDK8 in its truncated form cannot be verified with a western because the antibody used 
binds the C-terminus of CDK8, which is no longer present so a SYPRO Ruby gel is used as 
verification. Both the western blot and SYPRO Ruby gels verify successful purification of the 
truncation mutants from whole cell extracts and the concentrations were used to determine 
kinase loads in the kinase assays 
Figure 22. The SYPRO Ruby gels of CDK8 (1-357) and CDK8(1-403). The left is  
purified CDK8-CCNC dimers and the right is purified CDK8:CCNC:MED12:MED13.  
    HSP70 
    * 
HSP70 
* 
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Figure 23. Western blot of CDK8 Truncation Mutants. This shows the presence of all four 
proteins in the wild-type module and Δ403 module, but no MED12 or MED13 in the Δ357 
module (highlighted in red). All primary antibody dilutions are indicated  and the same 
secondary antibody, rabbit, at a 1:2000 dilution.  
 
Kinase Assay data between wild-type and mutant CDK8 modules 
After the CDK8 truncation mutants were purified, kinase assays were run for the 2-
protein and 4-protein modules to determine the activity of the mutated CDK8 proteins. The pol II 
CTD was used in all of the kinase assays, as it was previously proven that CDK8 phosphorylates 
the CTD in-vitro (Knuesel et al., 2009). All of the kinase samples used were added in relative 
amounts to the wild-type modules so that direct comparisons could be made between each of the 
three protein complexes.  
The first kinase assay with the two-protein complexes of CDK8:CCNC (Figure 24) 
showed kinase activity in the wild-type CDK8 module and comparable activity with the 
CDK8(1-403) truncation mutant but no activity was seen with the CDK8(1-357) truncation 
mutant, even at high concentrations. The second kinase assay with the four-protein complexes 
with CDK8:CCNC:MED12:MED13 (Figure 25) shows similar results to the two-protein 
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complex kinase assay. There is activity in the wild-type module, 2-4x reduced activity in the 
CDK8(1-403) truncation mutant, and greatly reduced activity in the CDK8(1-357) module. Each 
kinase assay was replicated at least twice to ensure the validity of the results. 
 
Figure 24. Kinase assays from CDK8:CCNC Truncation Mutants. This diagram shows the 
silver and autorad signals from the kinase assays. The silver shows the amount of protein in the 
sample and the autorad signals indicate the kinase activity of CDK8 as it auto-phosphorylates 
and phosphorylates the CTD.  
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Figure 25. Kinase assays from CDK8 Module Truncation Mutants. This diagram shows the 
silver and autorad signals from the kinase assays done with CDK8:CCNC:MED12:MED13 
normal module and with truncated CDK8. Again the silver shows the amount of protein in the 
samples and the autorad signals are indicative of the activity of CDK8 as it auto-phosphorylates 
and phosphorylates the CTD.  
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Figure 26. Relative Activity of Truncation Mutants in CDK8 Module with pol II CTD. For 
this quantification (n=1).  
 
 
Figure 27. Relative Activity of Truncation Mutants in CDK8 Module with CDK8. The 
average activity of the CDK8(1-403) truncation mutant compared to the wild-type module based 
on kinase activity (CDK8) for the four-protein modules. CDK8(1-357) was omitted due to the 
lack of a visible band of activity to quantify (n=1). 
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C. Discussion  
Regulatory role of CDK8 C-terminal domain (CTD) in CDK8-CCNC 
 From both of the kinase assays that were done with the CDK8 truncation mutants, 
differences can be seen in activity in comparison to the wild-type complexes. Since CDK8 is a 
kinase that phosphorylates other proteins, the auto-rad signal is indicative of how active the 
kinase is, with a stronger signal corresponding to higher levels of activity. Based on SYPRO 
Ruby gels, where the amount of protein was quantified from both the CDK8 and CCNC bands, 
equal amounts of protein were loaded as close as possible to be able to make inferences about the 
amount of activity in relation to the amount of kinase.  
In the 2-protein module, it can be seen that the wild-type CDK8:CCNC auto-
phosphorylates and also phosphorylates the CTD (Figure 24). The CDK8(1-403) truncation 
mutant shows comparable amounts of protein in relation to the CDK8 and pol II CTD, but has 
slightly less activity from its less intense band on the auto-rad, looking both at the CDK8-P and 
CTD-P bands (with the P standing for phosphorylated bands). Then looking at the CDK8(1-357) 
truncation mutant, there is much less activity in comparison to CDK8(1-403) and the wild-type 
CDK8-CCNC complex when looking at the pol II CTD-P bands and practically no activity in the 
CDK8-P region. This finding is quite interesting as it seems that the CDK8(1-357) truncation 
mutant is no longer able to auto-phosphorylate and phosphorylates the pol II CTD to a much 
lesser extent. This loss of auto-phosphorylation could be linked to either the last remaining auto-
phosphorylatable site being between residue 357 and 403 or it could be linked to the possible 
differences in the truncation mutant’s ability to bind MED12. Thus, the next step was to look at 
the truncation mutants in the full protein module. 
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Regulatory role of CDK8 C-terminal domain (CTD) in CDK8 Module 
In the 4-protein CDK8 module, there should be increases in activity with the CDK8(1-
357 truncation mutant, since it is known that MED12 is required for kinase activity (Knuesel et 
al., 2009). Looking at the silver stained gel, there are comparable amounts of kinase (CDK8) and 
of the pol II CTD in each of the samples, allowing for comparisons to be made between the 
different complexes (Figure 25). The kinase assay shows this in the wild-type CDK8 module, 
with dramatic increases in the pol II CTD-P signal and CDK-P signal, all coming from the 
addition of MED12 to the complex. In comparison, the CDK8(1-403) truncation mutant in the 
context of the 4-subunit CDK8 module shows decreased activity in the pol II CTD-P bands and 
in the CDK8-P bands, and it was estimated to be 2-4x less active (Figure 26, Figure 27). Then 
looking at the CDK8(1-357) complex, there is much less activity in the pol II CTD-P bands and 
practically no activity in the CDK8-P region. Again, there is a loss of auto-phosphorylation 
between the two CDK8 truncation mutants and introducing MED12 back into the CDK8 module 
did not increase kinase activity. Yet it was important to verify that all four proteins were present.  
A western was then run to verify how well the wild-type and truncation mutants were 
binding MED12 and MED13 (Figure 23). From the western, it was found that the wild-type and 
CDK8(1-403) complexes were able to bind MED12 and MED13 in comparable amounts but that 
the CDK8(1-357) complex was apparently unable to bind either MED12 or MED13. This can 
help to explain the lack of activity in the kinase assay of the four-protein modules as MED12 
was not present in the CDK8(1-357) samples and MED12 activates CDK8 kinase activity 
(Knuesel et al., 2008).  
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Significance of Data 
 From the kinase data and western blots, it appears that the CDK8 C-terminus is not acting 
as a traditional kinase activation loop. The original hypothesis was that increased levels of 
activity would be seen in the truncation mutants as the CDK8 C-terminus would no longer be 
able to block the active site of the kinase. Yet, from the kinase assays, decreased levels of CDK8 
kinase activity are seen rather than increased levels, indicating that the CDK8 C-terminus is not 
acting as a traditional activation T-loop. Still, other possibilities could be that chopping off over 
100 residues in the CDK8(1-357) truncation mutants could be causing a slight disorder in the 
structure of the protein, particularly near the C-terminus end, that could be affecting activity. As 
well, it could be that there is a residue located between residue 357 and 403 that needs to be 
phosphorylated that could be causing the C-terminus to be acting as a non-traditional activation 
loop, since there is a loss of auto-phosphorylation between CDK8(1-403) and CDK8(1-357) 
(Figure 22). Yet, of more immediate interest is the fact that CDK8(1-357) is unable to bind 
MED12 and MED13.  
More directly comparing the activity of the CDK8(1-357) truncation mutant in the 
CDK8-CCNC complex to the 4-protein CDK8 module, the activity levels are fairly similar when 
looking at the pol II CTD-P bands (Figure 26). This would be expected since CDK8(1-357) is 
unable to bind MED12 and indicates that the CDK8(1-357) protein is structured enough to 
phosphorylate the pol II CTD to some extent. Thus, this suggests that the CDK8 C-terminus is 
instead playing a structural role and is binding MED12 and/or MED13 to the CDK8 module. 
This is an extremely interesting finding as it was not clear that the CDK8 C-terminus was 
playing any structural function in the module, due to its inability to be crystallized with CCNC 
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(Schneider et al., 2009) and the lack of cross-links found with MED12 in previous experiments. 
Yet, at this point, the cross-linking data are inconclusive due to a lack of sample.  
From this information, I propose two possible models for how the C-terminus of CDK8 
may be influencing MED12 binding. One model is that the CDK8 C-terminus is binding, 
intramolecularly, with the rest of CDK8 and/or CCNC, causing a structural shift in the dimer that 
would allow MED12 and MED13 to bind to CDK8-CCNC (Figure 28). Therefore, when the 
CDK8 C-terminus is truncated, that structural shift does not occur and so MED12 and MED13 
can no longer bind the CDK8-CCNC dimer. The second model is that the CDK8 C-terminus is 
directly binding MED12 and/or MED13 (Figure 29), so when the CDK8 C-terminus is removed, 
MED12 and/or MED13 can no longer interact with the CDK8-CCNC dimer. These two models 
could be how the C-terminus of CDK8 is influencing MED12 binding, but there are still other 
possibilities beyond these two mechanisms.  
 
 
Figure 28. One possibility of the CDK8 C-terminus influencing MED12 binding. This model 
shows how the CDK8 C-terminus could be interacting with CDK8 and/or CCNC, causing a 
structural shift that would allow MED12/MED13 to bind. When the C-terminus is removed, 
MED12/MED13 can no longer interact with CDK8 and CCNC.  
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Figure 29. Second possibility for the CDK8 C-terminus influencing MED12 binding. This 
model shows how the CDK8 C-terminus could be directly binding MED12, MED13, or both 
proteins. So when the CDK8 C-terminus is removed, MED12 and/or MED13 can no longer 
interact with MED12 and MED13.  
 
Other possibilities could be that the CDK8 C-terminus is binding MED13, which then 
causes some shift allowing MED12 to then bind to the module. This possibility is further 
indicated by CXMS data from Ben Allen (graduate student in the Taatjes lab), where two “high-
confidence” cross-links were found between MED13 and CDK8. Another possibility could be 
that the CDK8 C-terminus undergoes from being unstructured to structured as it binds MED12, 
not allowing it to be crystallized in the 2-protein module. Ultimately, there are multiple 
possibilities to how the CDK8 C-terminus is interacting with MED12 in activating the kinase, 
but this is a promising finding in determining the function of the C-terminus of CDK8.  
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Figure 30. A summary of results with the CDK8 truncations in relation to the kinase 
activity of CDK8.  
 
Future Directions 
In order to get a better idea of how the C-terminus may be vital for binding MED12 
and/or MED13 to the CDK8 module, there are a variety of experiments that could be done. One 
of the first experiments that could be done would be to run a western blot of whole cell extract 
(WCE) from insect cells producing the truncation mutant CDK8(1-357), to ensure that MED12 
and MED13 are present so that we know that the lack of MED12 and MED13 in the purified 
protein samples is related to loss of CDK8’s C-terminus. Another future experiment would be to 
express GST tagged CDK8 residues 357 to 464, which represents the entire C-terminus of 
CDK8. By binding the CDK8 C-terminus to glutathione beads and pouring whole cell extract 
from insect cells that express the entire CDK8 module (MED12, MED13, CDK8, CCNC) and 
looking at what the CDK8 C-terminus pulls down could produce interesting data. If, for 
example, the CDK8 C-terminus (residues 357-464) were able to pull down MED12 and/or 
MED13, this would be a strong indication that the CDK8 C-terminus is binding either one or 
both. Very similarly, one other possibility would be to express CDK8:CCNC and then 
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MED12:MED13 separately in insect cells and then combine the whole cell extracts to see if the 
two protein dimers are able to bind one another to form complete CDK8 modules. The same 
could also be done for the CDK8 truncation mutants in the 2-protein module to see if either 
CDK8(1-403) or CDK8(1-357) could bind MED12:MED13, which again could prove that the C-
terminus is required for binding MED12 and/or MED13.  
Additionally, the CDK8 truncation mutants could be sent to Dr. Ranish for CXMS and 
looking at how truncating the C-terminus may affect cross-links in the dimer, trimer, and full 
CDK8 module. If the CDK8 C-terminus is required for binding any of the other proteins in the 
module, changes in the cross-links, as compared to the wild-type modules that have been or will 
be cross-linked, could indicate a structural role for CDK8’s C-terminus 
Another interesting experiment could be to switch the C-terminus sections of CDK8 with 
CDK19. CDK8 and CDK19 are paralogs and form their own subfamily of CDKs, which is 
informative of their closely related nature (Manning, 2014). As well, they share a very similar 
primary sequence (92%) apart from their C-terminal regions (Figure 31) (Galbraith et al., 2013), 
which could alter how each CDK interacts with other protein complexes (Sato et al., 2004). As 
well, CDK19 has been shown to be able to form modules, similarly to CDK8 (Daniels et al., 
2013). Therefore, an interesting experiment would be to switch the C-terminus of CDK8 with the 
C-terminus of CDK19 and do purifications of the 4-protein module. This may help to determine 
whether it is the sequence of the C-terminus that is required for interaction with MED12 or if it is 
somehow a particular interaction within the full protein module with CDK8 and MED13 that is 
allowing the CDK8 C-terminus to bind MED12. As well, the CDK8 C-terminus could be binding 
MED13, which could be causing additional conformational changes to allow the binding of 
MED12. Overall, there are multiple experiments that could be performed in the future to try and 
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get a better picture of how the CDK8 C-terminus may be activating the kinase activity of CDK8 
by interacting with MED12.  
 
Figure 31. The C-terminus alignments of CDK8 and CDK19. Shows how the sequences 
differ in the C-terminal regions of both CDKs (Galbraith et al., 2013).  
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Chapter IV. Experimental Methods and Procedures 
 
Expression of  CDK8:CyclinC and CDK8:CyclinC:MED12 in insect cells  
 The expression has already been done by a specialized lab, the University of Colorado 
Protein Production, Monoclonal Antibody, Tissue Culture Core in Denver, from which the insect 
cells are ordered after being created in the Taatjes Lab. The insect cell pellets were then lysed to 
separate the soluble and insoluble proteins. A pestle is used to crush the cells open with pressure 
and then the solution is spun down at 55,000 RPM for 45 minutes to pellet the cells. The solution 
is then collected in 2mL aliquots.  
 
Purification of the CDK8 subcomplexes and truncation mutants 
 33 µL of Glu-Glu peptide is added to 125 µL of glutathione fast-flow beads and 33 for 
every 8 mL of whole cell extract (WCEG). The peptide binds overnight. The WCEG is added to 
the beads and binds for 4 hours at 4°C. The beads are spun down, the solution is removed, and 
then the beads are washed five times with 0.5M HEGN and three times with 0.15M HEGN. Glu 
peptide is then added in the same amount as the dry bead volume (100 µg for 8 mL) to compete 
with the protein for binding, forcing the CDK8 subcomplex to elute off the column. Two elutions 
are done for 45 minutes at 4°C and then a third elution at half of the bead volume is done for 30 
minutes at 4°C. The elutions are run through a spin filter at 4°C at 12,000 RPM to remove any 
beads. Samples are stored at -80°C.  
Western Blots 
A 9% polyacrylamide gel is run to completion and then transferred onto a nitrocellulose gel  
This is done with a Western blot. A gel is run and then transferred onto a nitrocellulose gel in 
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transfer buffer (10% 10x running buffer, 10% MeOH, 80% MiliQ H2O) at 100 V and .25 Amps. 
The gel is cut above 75 kDa to probe for MED12 , between 75kDa and 50kDa for CDK8 and 
below 50 kDa for cyclin C (CDK8=55 kDa, Cyclin C=33 kDa, MED12=243 kDa). The gel is 
washed in 5% milk in TBS-T to block the gel to decrease background signals. Primary antibodies 
are added to each gel section (CDK8 and cyclin C are added in 1:500 dilution = 10 µL, MED12 
is 1:1000 = 5µL). The antibody is left overnight in 5 µL of 5% milk at 4°C. The gel is washed in 
TBS-T and then the secondary antibody is added (CDK8=5µL of anti-goat, cyclin C, 
MED12=2.5µL of anti-rabbit) for 1 hour at room temperature in 5% milk. The gel is then 
developed with a chemiluminescent agent to create phosphorescence of he proteins and then 
using photo paper, an image of the gel is developed.  
 
SYPRO Ruby Staining for Quantitative Determination of Protein Amount 
 A 9% polyacrylamide gel is run and the gel is first fixed with a solution containing 50% 
methanol and 7% acetic acid for 30 minutes. Then the gel is stained with 60 mL of SYPRO Ruby 
gel stain and is shaken overnight at room temperature and must be covered in foil to prevent light 
exposure. The gel is then washed with a solution containing 10% methanol and 7% acetic acid 
and is washed in 100 mL for 30 minutes. An image is then taken using a Typhoon scanner and 
ImageJ software is used to calculate the amount of each protein (CDK8, cyclin C, MED12).  
 
Concentration of Protein Samples 
 For the CDK8:CyclinC:MED12 complex, a glycerol gradient is run with 30%, 20%, and 
15% glycerol layers to achieve greater 1:1:1 concentrations of each subunit. The gradient is 
poured into a 2mL centrifuge tube and then a small sample of the three-protein complex is 
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poured on top (200µL). The gradient is spun for 6 hours at 4°C at 55,000 RPM and 50-100µL 
fractions are collected.  
 The elution samples are run through a size cut-off filter (30K) and the sample is 
concentrated 5X per spin at 14,000 RPM at 4°C for between 2-4 minutes. The buffer is also 
exchanged with a modified 0.15M HEGN to remove any possible contaminants for the cross-
linking. The sample is concentrated 50-100x and then stored at -80°C until they are shipped to 
the Ranish Lab.  
 
Chemical cross-linking and mass spectrometry  
For detailed methods, please refer to Appendix 1 and (Luo, Fishburn, Hahn & Ranish, 2012).  
 
Single Direct Mutation with Stop Codon (TAA) 
 The primary sequence for the CDK8 protein has been previously determined in the lab. 
Two mutants were created, referred to as 1-357 K8 and 1-403 K8. The wild-type CDK8 protein 
is typically 464 amino acid residues long. The C-terminus was truncated at residue 357 since 
CDK8 in yeast is not as long and lacks the extended C-terminus. The truncation at 403 was 
determined as it is where the density from the crystal structure ends, suggesting the start of the c-
terminus arm, and this mutant was also shown to bind cyclin C.  
For each mutant, a primer was created to introduce both a stop codon at either 357 or 
403, along with a restriction enzyme site. The sequences are listed below, with the stop codon in 
italics and the restriction enzyme in bold.  
The 357sense sequence (Restriction Enzyme SspI):  
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GTCAAATCCCTTACCCAAAACGAGAATAATATTTAACGGAAGAAGAACCTGATGAC
AAAGG 
The 403sense sequence (restriction enzyme PmlI): 
CACACACAGGGACCCCCGTTGAAGAAATAACACGTGAGAGTTGTTCCTCCTACCACT
AC 
The primers are used to perform a polymerase chain reaction (PCR) to amplify the 
sequence of DNA from the CDK8 sequence we are trying to insert into the DNA vector. The 
full-length DNA is then digested with the restriction enzymes (EcoRI-HF and XbaI) to cut out 
the full-length CDK8 sequence. The digestion is run on an agarose gel to separate the bands, 
along with the PCR sequences of the truncated DNA. The bands are cut out of the gel and the 
DNA is purified using kits from Omega Bio-Tek using the manufacturer’s protocol for gel 
purification. The purified DNA plasmid is then added onto XL-10 E.coli cells to transform the 
bacteria. The E.coli are grown on plates with ampicillin overnight. A single cell culture is then 
collected, grown into a 3mL culture, then grown in a 1L culture, and then spun down.  
The cells are lysed and the DNA collected using the manufacturer’s protocol from the 
Omega Bio-Tex mini-prep kit. The DNA is digested with the added restriction enzymes (SspI 
and PmlI then run on an agarose gel to determine the accuracy of the DNA plasmid. The DNA is 
then sent to GeneWiz for sequencing and if accurate, the DNA is then transformed into bacteria 
once more and then the DNA plasmid is purified using the manufacturer’s protocol from the 
Omega Bio-Tek protocol from the maxi-prep kit. The plasmid is then sent to University of 
Colorado Protein Production, Monoclonal Antibody, and Tissue Culture Core in Denver to be 
viralized into insect cells.  
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Kinase Assays of CDK8 Mutants in CDK8-CCNC dimers and CDK8 Module 
 Based on the concentrations determined from a SYPRO Ruby gel, varying amounts of the 
mutants will be loaded onto a large gel. The reaction buffer consists of 25mM Tris at pH 8.0, 
100mM KCl, 2mM DTT, 100µM ATP (cold), 10mM MgCl2, and 2.5µCi of ATP (hot). CTD (C-
terminal domain) is added, along with 100mM KCl, and the kinase component (CDK8 mutants). 
The reaction is incubated at 30°C for 1 hour and then run on a 9% polyacrylamide gel.  
 A silver staining technique is used to stain the gel. Shake the gel in 50% methanol for 10 
minutes, 5% methanol for 10 minutes, 3.5µM DTT for 5 minutes, followed by 10 minutes in 
silver nitrate solution (250mL water, 250mg silver nitrate, 25µL formaldehyde). The gel is 
washed a few times, for no more than 10 seconds, in water. Rinse the gel briefly with sodium 
carbonate solution (500mL of cold water, 15g sodium carbonate, 250µL formaldehyde) and then 
pour the whole solution onto the gel. Once the gel is thoroughly developed, quench with citric 
acid monohydrate and then rinse the gel in a large volume of water 
 Then a storage PhosporScreen (GE Healthcare) is used, along with a Typhoon Scanner, to 
view the activity of the radioactively labeled subunits.  
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